We are live on ! Find out more
NAUT icon

Nautilus Biotechnolgy

68 hedge funds and large institutions have $48.9M invested in Nautilus Biotechnolgy in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $43.3M → $48.9M (+$5.6M)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1.53% less ownership

Funds ownership: 47.37%45.84% (-1.5%)

4% less funds holding

Funds holding: 7168 (-3)

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

72% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 29

Holders
68
Holders Change
-3
Holders Change %
-4.23%
% of All Funds
0.89%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
9
Increased
8
Reduced
29
Closed
12
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Nisa Investment Advisors
76
Nisa Investment Advisors
Missouri
-$205 -283 Closed
EP
77
Essential Partners
California
-$17 -23 Closed
CCM
78
Cloud Capital Management
Washington
+$36 +49 New

NAUT Hedge Fund Activity: Q3 2025 in Review

68 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2025, worth a combined $48.9M — up 13% from $43.3M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NAUT and 9 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, adding an estimated $285K. The largest seller was ArchPoint Investors, exiting entirely with an estimated $451K sold.

  • 68 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2025, down from 71 in Q2 2025.
  • Funds reported $48.9M of Nautilus Biotechnolgy stock for Q3 2025, up 13% quarter-over-quarter.
  • 9 funds opened new Nautilus Biotechnolgy positions in Q3 2025 and 12 closed out, a net change of -3 holders.
  • The largest Nautilus Biotechnolgy buyer in Q3 2025 was Renaissance Technologies, an estimated $285K added.
  • The largest Nautilus Biotechnolgy seller in Q3 2025 was ArchPoint Investors, an estimated $451K sold.

Based on aggregated 13F filings for Q3 2025.